The FDA has accepted uniQure’s applicatoin for its Huntington’s disease gene therapy under priority review, alongside a tentative plan to convene an advisory committee meeting. | The FDA has accepted ...
Teva has given up on a key trial of one of its original lineup of innovative medicines. | Teva has given up on a key trial of ...
The PASI 90 rate, which is in line with the phase 2 result, looks competitive. Cross-trial comparisons can be unreliable, ...
The FDA has put a partial hold on Biosciences’ seizure study application over preclinical toxicity data and concerns about ...
Audax sees the propensity for IL-12 drugs to bind receptors on peripheral immune cells as a driver of the dosing and toxicity ...
The drug programs left behind after Jazz Pharmaceuticals' $820 million acquisition of Actio Biosciences have found a new home ...
Eli Lilly has dropped its phase 2 Alzheimer's disease program for mevidalen, marking another setback for the experimental ...
BioMarin is paying $70 million upfront to license a Fabry disease drug candidate, expanding the franchise it acquired through ...
During a public hearing Wednesday to discuss a newly proposed rare disease framework, FDA center director Michael Davis, M.D.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results